A proteomics signature of NASH
A proteomics signature of NASH
Global prevalence of nonalcoholic fatty liver disease (NAFLD) is presently 30% and increasing. While the majority of afflicted individuals have a relatively non-progressive form, i.e., nonalcoholic fatty liver (NAFL), a significant subset with nonalcoholic steatohepatitis (NASH) are more likely to progress to cirrhosis.
No pharmacological therapies are currently approved for NAFLD or NASH, and liver histology is the reference standard for identification of those at increased risk of progression. Despite the requirement of liver histology improvement as an endpoint for regulatory approval, several factors limit applicability of biopsy in clinical development, including invasiveness and attendant risks, and sampling and observer variability and costs.
As such, there is a high unmet need for non-invasive tests that can robustly and reliably assess NAFLD for diagnosis, prognosis, and monitoring purposes. Large-scale profiling of serum/plasma proteins (proteomics) increasingly demonstrates utility to identify changes that accurately reflect and predict disease states and outcomes, including the fibrosis component of NASH that is driven by disease activity and remains the most robust histological marker of prognosis.
Recently, longitudinal assessment of over 5,000 serum proteins in 636 individuals with histologically confirmed NAFLD was used to develop and validate models for all four key individual liver biopsy components (steatosis, hepatocellular ballooning, lobular inflammation, fibrosis) and at-risk NASH, and with sufficient sensitivity and precision to characterize drug intervention-related changes. Taken together, these results support continued validation of such proteomics-based models and their promise to enable a “liquid biopsy” assessment of NAFLD.
Learning objectives
- Needs and applications of non-invasive testing for liver disease
- Basics of aptamer-based proteomics assessment and compared to standard clinical blood testing
- Current applications of proteomics biomarkers for unmet needs in NAFLD and NASH
Arun Sanyal, MBBS, MD
Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Interim Chair and Professor, Division of GI, Hepatology & Nutrition
VCU Health System
A proteomics signature of NASH
A presentation by Arun Sanyal, MD, MBBS
More webinars
WebinarCorrelation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes
In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal(TM) NASH bundle test in a recently completed clinical trial.
WebinarHarnessing AI and proteomics for glioblastoma
The development and advancement of aptamer technology opens vast possibilities for unlocking the biocomplexity available within proteomics. Learn more about the powerful tools that are enabling the discovery and validation of clinically relevant biomarkers and accelerating research.
WebinarMapping the human mucosal immune response to respiratory viruses
Conventionally, human immune responses have been extensively characterized using blood. Immune cells, though abundant in blood, are also found in various tissues in varying numbers and with locally relevant functional specification. Assessing immune responses in the airways over the course of infection and convalescence is critical to comprehensively mapping immunity to respiratory viral infections including influenza and SARS-CoV-2.